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Stroke is one of the commonest causes of death and disability worldwide. To date, no 
neuroprotective agent is approved clinically for treatment of acute ischaemic stroke. PC12 
cell-based in vitro stroke model has been used widely to screen for neuroprotective agents. 
The most common approach is to differentiate PC12 cells into a neuronal phenotype and 
subject the differentiated cells to oxygen glucose deprivation (OGD) to simulate an 
ischaemic stroke. However, there are increasing reports showing certain PC12 cell variants 
either poorly or cannot differentiate into neuron-like cells. Additionally, optimisation studies 
for cell culture media and adhesive substrate for commonly-used PC12 variants are limited. 
This study aimed to optimise cell culture conditions of three commonly-used PC12 cell 
variants and test their response to nerve growth factor (NGF)-induced differentiation. PC12 
cells (Riken cell bank), PC12 Adh cells and PC12 Neuroscreen-1 (NS-1) cells were studied. 
Optimisation of cell culture media and adhesive substrates were done by comparing cell 
morphology in different media and substrates. Adaptation of the three PC12 cell variants to 
a serum-free supplemented media was necessary because drug intervention studies need to 
be done in the absence of serum to avoid confounding effects. Comparison of the NGF-
induced differentiation for the three PC12 cell variants was done by counting the percentage 
of neurite-bearing cells. The PC12 variant with the highest response to NGF underwent 
studies to optimise its duration of OGD. Differentiated-cells were subjected to different 
durations of OGD followed by measurement of cell viability and enzyme activity in the 
execution phase of apoptosis (caspase 3 and 7) to determine the optimal duration of OGD 
for in vitro stroke model. The in vitro model was validated by treating the OGD-treated cells 
with a known neuroprotectant, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) for 
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24 hours. The optimal culture media for PC12 cells (Riken) and NS-1 cells was found to be 
DMEM high glucose. Collagen IV was the best substrate for PC12 cells (Riken) and NS-1 
cells. PC12 Adh cells showed no preference for media or substrates. Both NS-1 cells and 
PC12 cells (Riken) were successfully adapted to serum-free supplemented media. However, 
PC12 Adh cells failed to grow in a serum-free supplemented media. NS-1 cells gave the 
highest NGF-induced differentiation (72.7 ± 9.1%) followed by PC12 cells (Riken, 36.0 ± 
5.6%) and PC12 Adh cells (6.9 ± 0.8%). NS-1 cells achieved optimal differentiation after 
three days of 150 ng/mL NGF treatment. The optimal duration of OGD to induce cell injury 
was three hours. Treatment with 8-OH-DPAT on NGF-differentiated NS-1 cells after three 
hours of OGD showed a significant reduction in apoptosis (p < 0.01, One-way ANOVA 
followed by post hoc Tukey's test). In conclusion, we have shown that each PC12 variant 
has differing requirements for media and adhesive substrates. NS-1 cells were the optimal 
PC12 cell variant for an in vitro stroke model due to its high level of NGF-induced 
differentiation. DMEM high glucose was the optimal media and collagen IV was the best 
substrate for NS-1 cells. We also provide the first report that 8-OH-DPAT is neuroprotective 
in NS-1 cells. We conclude that we have optimised and set up an in vitro stroke model to 
screen for potential neuroprotective agents. 
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Pengoptimuman Model Strok In Vitro berasaskan Sel PC12 untuk Penyaringan Agen 
Neuroprotektif yang Berpotensi 
ABSTRAK 
Penyakit Strok adalah salah satu penyebab utama kematian dan kecacatan di seluruh tetapi 
masih tiada agen neuroprotektif diluluskan untuk rawatan strok iskemia. Model strok in 
vitro berasaskan sel PC12 telah digunakan secara meluas untuk penyaringan agen-agen 
neuroprotektif. Pendekatan yang paling lazim digunakan adalah membezakan sel PC12 
kepada fenotip neuron dan mendedahkan sel tersebut kepada keadaaan kekurangan glukosa 
dan oksigen (OGD) untuk mensimulasikan strok iskemia. Walau bagaimanapun, terdapat 
peningkatan laporan yang menunjukkan varian sel PC12 tertentu yang tidak dapat atau 
kurang berupaya untuk berbeza kepada sel seperti neuron. Kajian pengoptimuman untuk 
media kultur sel dan substrat perekat untuk varian PC12 yang lazim digunakan adalah 
terhad. Kajian ini bertujuan untuk mengoptimumkan keadaan kultur sel untuk tiga varian 
sel PC12 dan menguji tindak balas mereka terhadap pembezaan dengan faktor pertumbuhan 
saraf (NGF). PC12 (bank sel Riken), PC12 Adh dan PC12 Neuroscreen-1 (NS-1) telah 
dikaji. Pengoptimuman media kultur sel dan substrat pelekat dilakukan dengan 
membandingkan morfologi tiga varian sel dalam media dan substrat pelekat yang 
berbeza. Penyesuaian varian sel tiga PC12 ke media tambahan tanpa serum adalah perlu 
kerana kajian ubat baru perlu dilakukan tanpa serum untuk mengelakkan kesan yang 
mengelirukan. Perbandingan tindak balas kepada pembezaan yang disebabkan oleh NGF 
untuk tiga varian sel telah dilakukan dengan mengira peratusan sel yang mengandungi 
neurit. Varian sel yang menunjukkan tindak balas tertinggi kepada NGF digunakan 
untuk mengoptimumkan tempoh OGD. Sel tersebut tertakluk kepada tempoh OGD yang 
berlainan dan diikuti dengan pengukuran daya aktif sel dan aktiviti enzim dalam fasa 
pelaksanaan apoptosis (caspase 3 dan 7) untuk menentukan tempoh optimum OGD. Model 
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strok in vitro disahkan dengan merawat sel yang telah dicedera oleh OGD dengan 
menggunakan agen neuroprotektif yang dikenali sebagai 8-hydroxy-2-(di-n-propylamino) 
tetralin (8-OH-DPAT) selama 24 jam. Hasil kajian menunjukkan media kultur optimum 
untuk PC12 (Riken) dan NS-1 adalah DMEM tinggi gula. Kolagen IV adalah substrat 
terbaik untuk PC12 (Riken) dan NS-1. PC12 Adh tidak menunjukkan keutamaan dalam 
mana-mana media atau substrat. NS-1 dan PC12 (Riken) berjaya disesuaikan dengan media 
tambahan tanpa serum dan dapat hidup di media tersebut. Walau bagaimanapun, PC12 
Adh gagal berkembang dalam media tambahan tanpa serum. NS-1 menghasilkan 
pembezaan yang disebabkan oleh NGF (72.7 ± 9.1%) yang tertinggi diikuti oleh PC12 
(Riken, 36.0 ± 5.6%) dan PC12 Adh (6.9 ± 0.8%). Sel NS-1 mencapai pembezaan optimum 
selepas tiga hari rawatan 150 ng/mL NGF. Tempoh optimum OGD untuk merangsang 
kecederaan sel adalah tiga jam. Rawatan dengan 8-OH-DPAT pada sel NS-1 yang telah 
dibezakan selepas tiga jam OGD menunjukkan pengurangan apoptosis yang signifikan 
(p < 0.01) (satu arah ANOVA diikuti oleh ujian Tuki post hoc). Kesimpulannya, kami telah 
menunjukkan bahawa setiap varian PC12 mempunyai keperluan berbeza untuk media dan 
substrat pelekat. Kami melaporkan bahawa 8-OH-DPAT adalah neuroprotektif dalam NS-
1 dengan kali pertama. NS-1 adalah varian sel PC12 yang optimum untuk model strok in 
vitro kerana mempunyai tahap perbezaan oleh faktor NGF yang paling tinggi berbanding 
dengan dua varian PC12 yang lain. DMEM tinggi gula adalah media optimum dan kolagen 
IV adalah substrat terbaik untuk NS-1. NS-1 yang didedahkan kepada tiga jam OGD 
menyerupai strok iskemia. Kesimpulannya, kami telah mengoptimumkan dan menubuhkan 
model strok in vitro untuk menyaring agen-agen neuroprotektif yang berpotensi. 
Kata kunci: Strok, sel PC12, substrak pelekat, pembezaan dengan faktor pertumbuhan 
saraf, kekurangan glukosa dan oksigen, apoptosis, agen-agen neuroprotektif 
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INTRODUCTION AND LITERATURE REVIEW 
 Stroke 
  
Stroke is the second commonest cause of death worldwide (Katan & Luft, 2018). 
Its global burden is high, inclusive of increasing mortality, incidence, disability-adjusted life 
year and economic impact, particularly in low- and middle-income countries (Mukherjee & 
Patil, 2011). It can cause cognitive and functional disabilities, contributing significantly to 
long term health care costs (Azad, Veeravagu, & Steinberg, 2016). In Malaysia, stroke is the 
third leading causes of death (Department of Statistic Malaysia, 2018). The incidence of 
local ischaemic stroke is on the trend of rising annually by 29.5% (Lee, Shafie, Sidek & 
Aziz, 2017). The prevalence of stroke was reported as 0.7%, with 1.7% among those aged 
55-59 years, 2% in 60-64 years, 3% in 65-69 years, 3.5% in 70-74 years and 7.8% in 75 
years and beyond in the fourth National Health and Morbidity Survey (NHMS) in 2011 
(Ministry of Health Malaysia, 2011). Prognosis of the disease depends on many factors 
including age, stroke severity, infarct location, stroke mechanism, clinical findings and 
related complications. In addition, medical interventions for example thrombolysis, 
thrombectomy, stroke unit care, and rehabilitation influences the outcome of the disease.   
 
  Pathogenesis of Stroke 
 
Stroke are caused by ischaemia (loss of blood supply) or haemorrhage (bleeding). 
Around 80% of stroke are caused by ischaemia. The most common ischaemic strokes include 
